With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...

Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Results from the company’s Phase III Mint trial marked a median three-point improvement on a scale used to measure symptom ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $40 from $45 and keeps a Buy rating on the shares. The firm ...

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...